Rhinocerebral mucormycosis in the era of lipid-based amphotericin B: Case report and literature review

Kristin E. Mondy, Bruce Haughey, Philip L. Custer, Franz J. Wippold, David J. Ritchie, Linda M. Mundy

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Rhinocerebral mucormycosis (RCM) is an invasive fungal infection that necessitates, in most cases, aggressive surgical debridement and high cumulative, often nephrotoxic doses of amphotericin B. A 50-year-old woman with RCM was treated successfully with amphotericin B lipid complex as primary therapy. The patient previously had displayed progressive intracranial involvement and rising serum creatinine levels while receiving the conventional (nonlipid) form of amphotericin B. A literature review identified only a few cases where systemic antifungal therapy was administered, with minimal or no surgery. Our case further supports that amphotericin B lipid complex can be used as primary therapy in selected patients with RCM, without the need for surgical exenteration.

Original languageEnglish (US)
Pages (from-to)519-526
Number of pages8
JournalPharmacotherapy
Volume22
Issue number4
DOIs
StatePublished - Jan 1 2002

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Rhinocerebral mucormycosis in the era of lipid-based amphotericin B: Case report and literature review'. Together they form a unique fingerprint.

Cite this